Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

New York City Pain Specialists Introduce New Treatment for Knee Pain; First Physicians in Northeast to Offer iovera° Treatment
  • USA - English


News provided by

Myoscience

Feb 23, 2015, 03:00 ET

Share this article

Share toX

Share this article

Share toX


Redwood City, CA (PRWEB) February 23, 2015 -- The iovera° system, cleared by the FDA to treat peripheral nerve pain, utilizes its patented Focused Cold TherapyTM delivery system to direct a controlled cold dosage via closed-end probes to specific nerves for precise, predictable, drug-free pain relief.

Sudhir Diwan, M.D., Manhattan Spine and Pain. “My patients are excited to have a minimally-invasive, drug-free treatment that enables them to walk out of my office pain-free and stay that way for up to 3 months.”

Post this

“The iovera° treatment provides my knee pain patients with a very effective, natural option that provides relief precisely at their point of pain allowing them, in many cases, to avoid or reduce their need for systemic painkillers,” said Sudhir Diwan, M.D., Manhattan Spine and Pain. “My patients are excited to have a minimally-invasive, drug-free treatment that enables them to walk out of my office pain-free and stay that way for up to 3 months.”

“Patients are relieved when they realize that there is a minimally-invasive, non-systemic option that can give them instant knee pain relief,” said Halland Chen, M.D., of Dr. Halland Medical. “There’s something familiar and comforting to patients about using the simple power of cold to eliminate pain, and with iovera° we can now use cold in a very high-tech, precise way to block specific nerve signals temporarily.”

Frequent knee pain limits function and mobility, and impairs quality of life for approximately 25% of adults.1 Peripheral nerves treated with the iovera° system are temporarily stopped from signalling for a period of time, followed by a restoration of function - results may vary per patient*. Because peripheral nerve function is disrupted rather than destroyed, the results are safe, effective and temporary.

“We are so pleased that these pain specialists have seen the unique value of the Focused Cold Therapy delivery system for patients with knee pain,” said Jeff Gold, myoscience CEO. “The iovera° treatment allows physicians to target a patient’s pain directly at the source by treating the specific peripheral nerves involved with a natural, safe dose of cold that temporarily stops the nerves from signalling and delivers immediate pain relief.”

The iovera° system delivers liquid nitrous oxide from a convenient and powerful handheld device to the closed-end probes of the Smart Tip during treatment. While this highly pressurized liquid travels from the handpiece to the Smart Tip, it undergoes a phase change becoming very cold, drawing in heat energy from the surrounding tissue and forming a precise zone of cold at thetargeted nerve. The gaseous nitrous oxide returns into the handpiece, leaving nothing behind in the body. This precise cold treatment causes a reversible nerve block based on a process called Wallerian degeneration. Pain is relieved in sensory nerves, which send messages to the central nervous system. The nerve re-innervates 1-2 mm per day, which gives a predictable restoration of nerve function.

About iovera°
The Food and Drug Administration (FDA) cleared the iovera° system for use in peripheral nerves in January 2013. iovera° is being used most frequently for knee pain but can be used to treat pain in any peripheral nerve. The iovera° system is specifically cleared to destroy tissue during surgical procedures by applying cold temperature. It can also be used to produce lesions in peripheral nervous tissue by the application of cold to the selected site for the blocking of pain. The iovera° system is not indicated for treatment of central nervous system tissue.

About the Manhattan Spine and Pain Medicine
Manhattan Spine and Pain Medicine physicians listen and treat pain without surgery. Their passion is improving patients’ quality of life. Pain management is the medical specialty focused solely on treating patients in acute and chronic pain. The practice’s goal is to restore function and improve the quality of life for those in pain. The board-certified physicians at Manhattan Spine and Pain listen diagnose and treat pain from head to toe using a range of non-surgical treatment options. For more information about the Manhattan Spine and Pain Medicine please visit: https://treatingpain.com/mspm. Patients interested in iovera° treatment at Manhattan Spine and Pain can call 877-463-7264.

About Dr. Halland Medical
Dr. Halland Chen specializes in pain management. His practice is focused on non-surgical knee and spine treatments, with a special emphasis on regenerative medicine and organic options through the use of PRP, Stem Cells and natural supplements. Dr. Halland Medical applies its unique techniques for patients to address sports injuries, pain management conditions, and cosmetic anti-aging. Dr. Halland specializes in injection therapy and minimally invasive techniques. For more information about Dr. Halland Medical please visit: http://drhalland.com. Patients interested in iovera° treatment at Dr. Halland Medical can call: 212-464-8772.

ABOUT MYOSCIENCE
Silicon Valley, California-based myoscience is a privately-held medical device company committed to making its platform technology, Focused Cold Therapy, the standard of care for the treatment of peripheral nerve conditions. Focused Cold Therapy is the patented technology delivered by the ioverao system. The ioverao system is currently approved in Europe and Canada for temporary wrinkle reduction, temporary pain reduction and treatment of dermatologic conditions, and is indicated in the United States for use in pain management and general surgical use. For more information, please visit http://www.myoscience.com.

© 2014 myoscience. All rights reserved. iovera° and Focused Cold Therapy are trademarks of myoscience. MKT-0338 REV A

  • In a single arm, post-market study of knee pain, 70% of subjects reported an effect at ~2 months. 45% of subjects reported a continued effect at ~3 months.

1 Nguyen, Uyen-Sa D.T., DSc, et al. “Increasing Prevalence of Knee Pain and Symptomatic Knee Osteoarthritis,” Ann Intern Med. (2011 December 6); 155(11): 725–732.

Denise Keeler, Myoscience, +1 (650) 465-9709, [email protected]

Modal title

Press Release
View PDF
Press Release
Press Release

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.